Clene (CLNN) Competitors

Senti Biosciences (NASDAQ:SNTI) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.

Do insiders & institutionals believe in SNTI or CLNN?

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 10.7% of Senti Biosciences shares are held by insiders. Comparatively, 35.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is SNTI or CLNN more profitable?

Senti Biosciences has a net margin of 0.00% compared to Clene's net margin of -8,556.77%. Senti Biosciences' return on equity of -154.84% beat Clene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-154.84%	-77.42%
Clene	-8,556.77%	-1,106.30%	-85.11%

Does the media favor SNTI or CLNN?

In the previous week, Senti Biosciences had 6 more articles in the media than Clene. MarketBeat recorded 8 mentions for Senti Biosciences and 2 mentions for Clene. Clene's average media sentiment score of 0.63 beat Senti Biosciences' score of 0.34 indicating that Clene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senti Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings & valuation, SNTI or CLNN?

Clene has lower revenue, but higher earnings than Senti Biosciences. Clene is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$2.56M	33.62	-$71.06M	-$12.03	-0.28
Clene	$342K	75.03	-$49.50M	-$5.75	-0.52

Which has more volatility and risk, SNTI or CLNN?

Senti Biosciences has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500. Comparatively, Clene has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Does the MarketBeat Community prefer SNTI or CLNN?

Clene received 78 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 81.19% of users gave Clene an outperform vote while only 40.00% of users gave Senti Biosciences an outperform vote.

Company	Underperform	Outperform
Senti Biosciences	Outperform Votes 4 40.00%	Underperform Votes 6 60.00%
Clene	Outperform Votes 82 81.19%	Underperform Votes 19 18.81%

Do analysts prefer SNTI or CLNN?

Senti Biosciences presently has a consensus target price of $10.00, indicating a potential upside of 202.11%. Clene has a consensus target price of $50.20, indicating a potential upside of 1,581.74%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than Senti Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Clene	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Summary

Clene beats Senti Biosciences on 11 of the 19 factors compared between the two stocks.